Importance of driver mutation assessment and driver-targeted therapy for early-stage NSCLC patients with non-R0 resection

This data includes the raw data of EGFR genotyping by MassARRAY MALDI-TOF nucleotide mass spectrometry platform (Agena Bioscience, San Diego, CA) in the recent study.

Abstract
Objective: Non-small cell lung cancer patients with incomplete resection have a worse outcome. We aim to identify the risk factors for disease progression and death. Methods: Between August 2011 and December 2020, early-stage NSCLC patients who underwent operation but had a non-R0 resection were included. We analyzed their clinicopathological features and driver mutation status. Results: A total of 65 patients were included for analysis. The median follow-up time was 36.2 months. Thirty-nine patients (60.0%) had experienced disease progression and 3 patients (4.6%) died. Twenty-two patients (33.8%) harbored driver mutation. In multivariate analysis, the presence of driver mutation predicted a higher risk of progression (adjusted OR 24.08 [95% CI 2.77-209.01], P = 0.004). ECOG PS 2 (adjusted HR 3.49 [95% CI 1.10-11.03], P = 0.033), higher tumor stage (adjusted HR 2.55 [95% CI 1.06-6.17], P = 0.037), and the presence of driver mutation (adjusted HR 3.28 [95% CI 1.55-6.94], P = 0.002) all predicted a shorter progression-free survival (PFS). Driver-targeted therapy was associated with a longer post-progression survival when patients were documented to have disease progression (adjusted HR 0.38 [95% CI 0.16-0.91], P = 0.030). There was no significant impact of driver mutation status on overall survival. Conclusions: Although the presence of driver mutation was associated with a higher risk of disease progression and a shorter PFS, patients with disease progression can benefit from driver-targeted therapy, which led to a similar overall survival with that of driver negative or unknown population; hence, comprehensive and earlier analyses of driver mutation are recommended.